SCHEMBL19668632

SCHEMBL19668632

c1ccc2nc(C3CCCN3)cnc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.48
CHRNB2 P17787 3/20 0.45
CHRNA4 P43681 3/20 0.45
CHRNA7 P36544 2/20 0.45
CYP1A2 P05177 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
MEN1 O00255 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
CYP2A6 P11509 1/20 0.41
CYP2C9 P11712 1/20 0.41
CHRM5 P08912 3/20 0.39
CHRM3 P20309 3/20 0.39
CHRM1 P11229 2/20 0.39
CHRM2 P08172 2/20 0.39
CHRM4 P08173 2/20 0.39
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6233129 0.79 CYP1A2 (0.41) CYP1A2SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL16429508 0.79 TAAR1 (0.49) TAAR1CHRNB2CHRNA4CHRNA7CYP1A2
SCHEMBL28177767 0.77 CYP1A2 (0.37) CHRNB2CHRNA4CHRNA7CYP1A2SMN1; SMN2
SCHEMBL28748650 0.75 CHRNB2 (0.50) TAAR1CHRNB2CHRNA4CHRNA7CYP1A2
SCHEMBL8918069 0.74 CYP2D6 (0.52) TAAR1CHRNB2CHRNA4CHRNA7CYP1A2
SCHEMBL28695999 0.74 HDAC4 (0.43) CYP1A2SMN1; SMN2POLBKDM4ENPC1
SCHEMBL3703819 0.73 MEN1 (0.55) CYP1A2SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL29590357 0.73 MEN1 (0.55) CYP1A2SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL20342557 0.73 HDAC4 (0.48) CYP1A2SMN1; SMN2POLBKDM4ENPC1
SCHEMBL20707 0.73 CHRNB2 (0.50) TAAR1CHRNB2CHRNA4CHRNA7CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190308987-A1 DUAL MODULATORS OF BOTH MU AND KAPPA OPIOID RECEPTORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
EP-3463361-A1 DUAL MODULATORS OF BOTH MU AND KAPPA OPIOID RECEPTORS Virginia Commonwealth University (US) 2019-04-10 EP disclosed
WO-2017210105-A1 DUAL MODULATORS OF BOTH MU AND KAPPA OPIOID RECEPTORS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190308987-A1 DUAL MODULATORS OF BOTH MU AND KAPPA OPIOID RECEPTORS OPRK1, OPRM1, OPRL1 TAAR1 39/4885CHRNB2 287/4885CHRNA4 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.